Is There Still a Role for First-Line Single Agent Endocrine Therapy in HR+ and HER2- Advanced Breast Cancer?

類似資料

• Managing advanced HR-positive, HER2-negative breast cancer with CDK4/6 inhibitors in post-menopausal patients: is there a best sequence?
  著者:: Rossi, Lorenzo, 等
  出版事項: (2018)
• Clinical Outcomes with First-line Endocrine Therapy or Chemotherapy in Postmenopausal HR+/HER2- Metastatic Breast Cancer
  著者:: Yan Song, 等
  出版事項: (2015-09-01)
• Clinical Outcomes with First-line Endocrine Therapy or Chemotherapy in Postmenopausal HR+/HER2− Metastatic Breast Cancer
  著者:: Song, Yan, 等
  出版事項: (2015)
• PHARMACOECONOMIC EVALUATION OF RIBOCICLIB FOR THE FIRST-LINE TREATMENT OF HR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER
  著者:: N. A. Avksentyev, 等
  出版事項: (2018-08-01)
• Everolimus plus exemestane as first-line therapy in HR(+), HER2(−) advanced breast cancer in BOLERO-2
  著者:: Beck, J. Thaddeus, 等
  出版事項: (2013)